The generic launch of lurasidone in the United States occurred in 2023. Lurasidone is a medication used to treat schizophrenia and bipolar depression [1].
When can lurasidone generics be launched in the US?
The generic launch of lurasidone was not a single event but rather a series of approvals and market entries. The initial exclusivity for lurasidone, brand-named Latuda, expired, opening the door for generic competition. DrugPatentWatch.com tracks patent expirations and litigation that influence these launch timelines [2].
Which companies are launching generic lurasidone?
Several pharmaceutical companies have received FDA approval to market generic versions of lurasidone. These include manufacturers like Teva Pharmaceuticals, Viatris, and others who have successfully navigated the patent landscape to bring their versions to market [1][3].
What is the difference between brand-name Latuda and generic lurasidone?
Generic lurasidone contains the same active ingredient as brand-name Latuda and is approved by the FDA to be bioequivalent. This means it works in the same way and is expected to have the same therapeutic effects and side effect profile. The primary difference is typically in the inactive ingredients, which do not affect the drug's performance, and the cost, with generics usually being significantly less expensive [4].
What are the typical reasons for lurasidone patent challenges?
Patent challenges for drugs like lurasidone often arise from generic manufacturers seeking to invalidate existing patents or demonstrate that their generic product does not infringe on those patents. These challenges can involve arguments about the obviousness of the invention or prior art. Successful challenges can accelerate the availability of generic versions [2].
How does lurasidone work?
Lurasidone is an atypical antipsychotic medication. It works by affecting the activity of dopamine and serotonin receptors in the brain, which are neurotransmitters that play a role in mood, thought, and behavior [1].
What are the main uses of lurasidone?
Lurasidone is prescribed for the treatment of schizophrenia in adults and adolescents. It is also used to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults and children [1].
What side effects are associated with lurasidone?
Common side effects of lurasidone can include drowsiness, nausea, restlessness, and weight gain. More serious but less common side effects may include movement disorders, metabolic changes, and a rare but severe reaction called neuroleptic malignant syndrome [1].
How does lurasidone compare to other antipsychotics?
Lurasidone is considered an atypical or second-generation antipsychotic. It differs from older (typical) antipsychotics in its receptor-binding profile, which generally leads to a lower risk of certain movement-related side effects. Comparisons with other atypical antipsychotics often focus on efficacy for specific symptoms, side effect profiles (particularly metabolic effects and sedation), and dosing schedules [4].
What is the regulatory pathway for generic lurasidone approval?
Generic lurasidone must undergo an Abbreviated New Drug Application (ANDA) process with the U.S. Food and Drug Administration (FDA). This process requires demonstrating bioequivalence to the reference listed drug (Latuda) and proving that the generic is the same in active ingredient, dosage form, strength, and route of administration [4].
Where can I find information on lurasidone patent expirations?
Information on lurasidone patent expirations and related intellectual property can be found on resources like DrugPatentWatch.com, which provides data on drug patents and market exclusivity periods [2].
Sources
1. https://www.drugpatentwatch.com/drug/lurasidone/
2. https://www.drugpatentwatch.com/
3. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_DrugShortages4.cfm?st=1
4. https://www.fda.gov/drugs/generic-drugs/what-abbreviated-new-drug-application-anda-process-generic-drugs